NAD+ Market Game-Changer: EffePharm Leads “Clinical & Compliance” Charge at SupplySide Global 2025

The North American anti-aging supplement market just hit a seismic shift: After years of anticipation, the FDA has officially greenlit NMN (nicotinamide mononucleotide) as a dietary supplement. For brands, manufacturers, and consumers, this isn’t just regulatory news; it’s a momentum to seize. Overnight, the NAD+ market has gone from niche to mainstream in the US market, with demand for science-backed, compliant ingredients skyrocketing.

At the epicenter of this revolution? EffePharm. The global leader in NAD+ manufacturing, bulk NMN supply, and liposomal supplement innovation stole the show at SupplySide Global 2025 in Las Vegas, wowing attendees with a portfolio built for the post-FDA era. To arm partners with more than just ingredients, with solutions: compliance shortcuts, clinical proof, and absorption breakthroughs. Here’s how EffePharm is turning the NAD+ boom into a win for brands ready to lead.

UTHEVER^® NMN – The Compliance-First Edge for NAD+ Manufacturers

Track to All Mainstream Market: UTHEVER^® NMN’s NDI & EFSA Lead

In light of the evolving regulatory framework for NMN, achieving a compliant market entry is the top priority for responsible brands. Success now hinges on partnering with an ingredient supplier dedicated to rigorous and transparent regulatory engagement.

EffePharm is committed to this process. In alignment with the FDA’s guidelines, we have resubmitted a New Dietary Ingredient (NDI) notification for UTHEVER^® NMN. Furthermore, our application for EFSA novel food certification is progressing. This ongoing work reflects our commitment to building a fully compliant pathway for our partners.

By choosing UTHEVER^®, you align with a partner actively investing in the regulatory process. Our aim is to help de-risk your development timeline and provide the substantiated documentation needed to pursue market access in North America and Europe with greater confidence.

As one SupplySide attendee put it: “UTHEVER^® isn’t just an ingredient, it’s a stamp of reliability. Consumers know it, retailers trust it.”

Clinical Data Redefines Efficacy of NAD+ Supplements

Beyond Hype: Human Trials Prove UthPeak^® NMNH & LipoAvail^® Work

The NAD+ space has long been plagued by “miracle claims” without data. EffePharm is changing that, with human trials. At SupplySide, they doubled down on two stars: UthPeak^® NMNH (the next-gen NAD+ precursor) and LipoAvail^® Liposomal NAD+ (the absorption breakthrough).

UthPeak^® NMNH: The Next-Gen NAD+ Precursor

Move over, standard NMN, UthPeak^® NMNH is here, and it’s bringing receipts. As the world’s first reduced NMN (NMNH) with large-scale, long-term human trials, UthPeak^® doesn’t just talk about efficacy, it proves it.
Clinical data from a 90-day study? Stunning: 300% higher NAD+ levels, and participants showed a 5-year biological age reduction. For brands tired of “proprietary blends” and lab-bench promises, this is the holy grail: real people, real results, real science.

Plus, UthPeak^® is self-GRAS certified, a critical checkbox for North American applications. As Addy Gao, Sales and Marketing Director of EffePharm, noted: “Consumers are done with hype. They want data. UthPeak^® gives brands exactly that, differentiation they can sell.”

LipoAvail^® Liposomal NAD+: Absorption Breakthrough

NAD+ supplementation sounds great in theory, until poor absorption tanks results. Enter LipoAvail^® Liposomal NAD+, EffePharm’s answer to the “delivery problem.”

Using biomimetic phospholipid bilayers (think: tiny, body-friendly “carriers”), LipoAvail^® navigates NAD+ past the gut’s absorption barriers. The result? Clinical proof: 150% higher bioavailability than standard NAD+ supplements. No more wasted ingredients, no more disappointed customers, just NAD+ that actually gets where it needs to go.

And EffePharm doesn’t cut corners on quality. Every batch of LipoAvail^® undergoes rigorous testing for encapsulation efficiency and stability, ensuring partners get consistent, high-performance liposomal NAD+, every time.

LipoAvail^® – The Liposomal Technology Powering Multi-Category Innovation

More Than NAD+: LipoAvail^® Unlocks Better Absorption for Vitamins, Antioxidants & Beyond

Here’s the secret EffePharm isn’t keeping: LipoAvail^® isn’t just for NAD+. It’s a liposomal technology-powered platform, one that’s revolutionizing absorption across the supplement aisle.

As a leading liposome manufacturer, EffePharm built LipoAvail^® to solve a universal problem: most supplements are poorly absorbed. Now, brands can apply that same breakthrough tech to any ingredient that struggles with delivery. Case in point:

• Liposomal Glutathione: 13x higher bioavailability than conventional forms.
• Liposomal Vitamin C: 7.86x better absorption for immune and collagen support.
• Liposomal Curcumin: 107.5x improved uptake (game over for inflammation and liver health).
• Liposomal Berberine: 33.3x higher absorption (metabolic health just got a boost).

For brands, this means endless innovation potential. It’s a way to make all our products better, more effective, more competitive, more trusted.”

SupplySide Global 2025 Highlights – Industry Cheers EffePharm’s Science-Driven Approach

The star of the show? Dr. Richard H. Kaszynski’s seminar, “Unlock The Power of NAD+” By the time Dr. Kaszynski walked through UthPeak^®’s 300% NAD+ boost data and LipoAvail^®’s absorption trials, standing room was gone. “This is what the industry needs,” one attendee tweeted. “No fluff, just science that moves the needle.”

But the real takeaway? The feedback from brands. Overwhelmingly, partners echoed the same priorities: clinical backing and fast compliance. “We don’t need another ingredient; we need a partner who gets the market,” said a supplement brand CEO. “EffePharm gets it. UTHEVER^® handles compliance, UthPeak^® handles efficacy, and LipoAvail^® handles absorption. That’s the trifecta.”

Partner with EffePharm – Lead the NAD+ Revolution

The NAD+ market isn’t just growing, it’s transforming. FDA approval has opened the floodgates, but only brands with the right ingredients, compliance, and clinical proof will thrive.

EffePharm isn’t just a manufacturer; they’re your shortcut to success. UTHEVER^® NMN for compliance and speed. UthPeak^® NMNH for clinical differentiation. LipoAvail^® for absorption that turns ingredients into results.

The NAD+ boom is here. Ready to lead? Partner with EffePharm, and turn the moment into a movement.

Contact EffePharm today to unlock your NAD+ growth strategy.